Interleukin 37 negatively associates with coronary plaque burden in psoriasis

Authors

• CL Harrington
• AK Dey
• Y Baumer
• AD Belur
• YA Elnbawi
• A Goyal
• Q Ng
• A Sajja
• GE Sanda
• AV Sorokin
• HL Teague
• NJ Varghese
• MP Playford
• NN Mehta

Abstract

Inflammation is associated with initiation and progression of atherosclerosis. Numerous studies have shown that psoriasis (PSO), a chronic inflammatory condition, is linked to increased risk for cardiovascular disease (CVD) development. Interleukin (IL)- 37 is a newly discovered anti-inflammatory member of the IL-1 cytokine family and has been shown to be regulated in inflammatory disease. Whether IL-37 is associated with subclinical CVD in PSO is not known. We hypothesized that the plasma levels of IL-37 in a PSO cohort would negatively associate with coronary computed tomography angiography (CCTA)-derived coronary plaque burden, a reliable marker of subclinical atherosclerosis. A cohort of PSO subjects (n=66) underwent CCTA scans as part of a large observational study to assess coronary plaque burden and IL-37 plasma levels were measured by ELISA assay. PSO patients were middle aged with low Framingham risk. In an unadjusted multivariable regression, IL-37 strongly inversely associated with both total coronary burden (ß=-0.30, p

Scientific Focus Area: Immunology

This page was last updated on Friday, March 26, 2021